GlassScriptPhysician profile
Christina Shellai Bowers
NPI 1326672338
$699.70
in general payments reported to CMS, 2019-2025
22 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.59 · 2022: $58.43 · 2023: $120 · 2024: $177 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $98.86 | 2024-2025 | |
| Astellas Pharma US INC | $62.49 | 2023-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.67 | 2021-2024 | Xifaxan |
| Novo Nordisk INC | $51.23 | 2022-2025 | Rybelsus, Ozempic |
| Amgen INC. | $39.09 | 2023-2025 | Krystexxa, Prolia, Evenity |
| Silk Road Medical, INC. | $35.44 | 2021 | |
| Janssen Pharmaceuticals, INC | $34.69 | 2025 | Spravato |
| Seqirus USA INC | $34.64 | 2025 | Fluad, Flucelvax |
| Exact Sciences Corporation | $32.92 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.94 | 2025 | Caplyta |
| Boston Scientific Corporation | $26.33 | 2025 | Intracept |
| Medtronic, INC. | $22.78 | 2022 | |
| Gilead Sciences, INC. | $22.66 | 2025 | Epclusa |
| Sanofi-Aventis U.S. LLC | $21.54 | 2024 | |
| Lilly USA, LLC | $21.54 | 2023 | Mounjaro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $19.00 | 2024 | Uptravi, Opsumit |
| Abbvie INC. | $17.71 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.54 | 2022 | |
| Sumitomo Pharma America, INC. | $15.01 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $13.78 | 2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $13.43 | 2024 | Fasenra |
| Glaxosmithkline, LLC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Bowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.